Core Viewpoint - Heptagon Pharmaceuticals-B (02142) has announced a share buyback plan of up to HKD 300 million, which was approved by shareholders at the upcoming annual general meeting on June 11, 2025. The company's stock price rose by 3.61% to HKD 12.34 with a trading volume of HKD 30.99 million [1][4]. Group 1: Share Buyback Announcement - The company plans to repurchase shares worth up to HKD 300 million in the open market [1][4]. - This buyback is subject to approval at the shareholders' meeting scheduled for June 11, 2025 [1][4]. Group 2: AI Drug Development Progress - Heptagon Pharmaceuticals-B has introduced recent advancements in its AI drug development business [1][4]. - The company launched the Hu-mAtrIx™ AI platform and established the first fully human AI HCAb model for generating and screening fully human heavy-chain antibodies [1][4]. - The company aims to integrate antibody engineering, AI-assisted drug discovery, and automated wet laboratories into a unified A3 large molecule innovative drug development platform, creating a feedback loop where extensive wet lab data enhances AI model training [1][4].
和铂医药-B早盘涨超3% 公司拟回购不超过3亿港元股份